Lupin’s subsidiary Lupin Manufacturing Solutions has commissioned a 4,270 m² oncology block in Vizag with high-containment systems, 20 reactors and integrated labs to support oncology API development across research and commercial stages.
Source: Lupin Press Release (NSE Exchange Fillings) | Published on Nov 12, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release of Lupin (NSE Exchange Filings), Lupin Manufacturing Solutions (LMS), a fully owned subsidiary of Lupin Ltd., has completed a sterilized high-containment oncology block within its facility in Vizag. This may be of interest to you if you track pharmaceutical manufacturing levels, oncology APIs, or the expansion of CDMO competencies. The oncology block enhances global oncology drug development capabilities for India at a time when demand for highly potent APIs is increasing.
4,270 m² oncology block commissioned
20 reactors ranging from 250 L to 2,000 L
Containment level maintained at ≤0.05 µg/m³
Batch range from 1 kg to 35 kg
Integrated labs for development and quality control
Also read: Mahindra & Mahindra and Manulife Sign 50:50 Life Insurance Deal
The oncology block covers 4,270 square metres and features sophisticated containment systems to maintain limits of exposure ≥0.05 µg/m³. As one can imagine, this is very important because oncology APIs have safety controls in place due to potency.
There are 20 reactors available at the facility, ranging from 250 L to 2,000 L, to facilitate development at various stages. The environmental controls are maintained at ≤25 °C and ≤45% RH to allow for production consistency.
The new unit comprises a dedicated Process Development Laboratory and Quality Control Laboratory. You will appreciate the facility, where both teams can now work within the same block. Collaborating within the same area creates a smooth path for transition from early-stage route scouting through to scale-up and ultimately to validation.
By reducing technical gaps that commonly delay oncology manufacturing, the new unit provides a foundation to support early-phase research, analytical development, process optimisation and commercial execution all co-located.
LMS has furnished the block with over 20 isolators, SCADA-linked operations, and a dedicated wastewater detoxification system. This represents your shift towards global-compliant manufacturing, where containment is a critical part of the regulatory requirements for oncology compounds.
This system enables scalable production by allowing clients to adjust their processes from gram-scale reactions to commercial-scale batches within the same facility layout.
Parameter | Detail |
Area | 4,270 m² |
Reactor Capacity | 250 L to 2,000 L |
Batch Scale Range | 1 kg to 35 kg |
Containment | ≤0.05 µg/m³ exposure levels |
Environmental Controls | ≤25 °C, ≤45% RH |
Labs Integrated | Process Development Laboratory + Quality Control laboratory |
Infrastructure | >20 isolators, SCADA systems, effluent detoxification |
The oncology API space is growing due to more research and development globally. With this block, LMS is enhancing its CDMO capabilities, providing clients with more choices from early development through commercial manufacturing.
This also aligns with industry-wide trends toward more integrated, high-containment ecosystems rather than fragmented ones.
Lupin share price stands at ₹2,033.90 per share on the BSE as of 12 November 2025 at 15:30 PM IST, up 2.94% from the previous close.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading